Brief: Volition Signs Exclusive $28 Million License, Supply Deal With Heska
29/03/2022 13:21
March 29 (Reuters) - VolitionRX Ltd VNRX.A :
* VOLITION SIGNS EXCLUSIVE $28 MILLION LICENSE AND SUPPLY
AGREEMENT WITH HESKA CORPORATION TO DISTRIBUTE NU.Q® VET CANCER
SCREENING TEST AT THE POINT OF CARE
Source text for Eikon: ID:nPn1bfjQLa
Further company coverage: VNRX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems